31 assets in Childhood Malignant Neoplasm

Therapeutic assets addressing Childhood Malignant Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
(+)-Vincristine Childhood Malignant Neoplasm	Tianjin Medical University Cancer Institute and Hospital	P2	BB (65)
Cyclophosphamide Childhood Malignant Neoplasm	St. Jude Children's Research Hospital	P2	BB (64)
Nivolumab Childhood Malignant Neoplasm	Australian & New Zealand Children's Haematology/Oncology Group	P2	B (62)
Dexasone Childhood Malignant Neoplasm	Yizhuo Zhang	P3	B (60)
Epirubicin Childhood Malignant Neoplasm	Children's Hospital Medical Center, Cincinnati	P2	B (60)
Irinotecan Childhood Malignant Neoplasm	Australian & New Zealand Children's Haematology/Oncology Group	P1/2	B (60)
Ondansetron Childhood Malignant Neoplasm	Yizhuo Zhang	P3	B (60)
OTL-38 Childhood Malignant Neoplasm	Mayo Clinic	P3	B (60)
Busulfanum Childhood Malignant Neoplasm	Malika Kapadia	P2	B (58)
Fludarabine Childhood Malignant Neoplasm	Malika Kapadia	P2	B (58)
Sorafenib Childhood Malignant Neoplasm	St. Jude Children's Research Hospital	P2	B (58)
Ipilimumab Childhood Malignant Neoplasm	Children's National Research Institute	P2	B (57)
Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- Childhood Malignant Neoplasm	Sun Yat-sen University	P2	B (57)
Arsenic Trioxide Childhood Malignant Neoplasm	Yang Li	P2	CCC (53)
Asparaginase Childhood Malignant Neoplasm	National Hospital Organization Nagoya Medical Center	P2	CCC (53)
Catequentinib Childhood Malignant Neoplasm	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Cytarabine Childhood Malignant Neoplasm	National Hospital Organization Nagoya Medical Center	P2	CCC (53)
Daunomycin Childhood Malignant Neoplasm	National Hospital Organization Nagoya Medical Center	P2	CCC (53)
Hydrocortisone Childhood Malignant Neoplasm	National Hospital Organization Nagoya Medical Center	P2	CCC (53)
Mercaptopurine Anhydrous Childhood Malignant Neoplasm	National Hospital Organization Nagoya Medical Center	P2	CCC (53)
Prednisolone Childhood Malignant Neoplasm	National Hospital Organization Nagoya Medical Center	P2	CCC (53)
Methotrexate Childhood Malignant Neoplasm	National Hospital Organization Nagoya Medical Center	P2	CCC (51)
Paxalisib Childhood Malignant Neoplasm	Australian & New Zealand Children's Haematology/Oncology Group	P1/2	CCC (48)
Atezolizumab Childhood Malignant Neoplasm	St. Jude Children's Research Hospital	P1/2	CC (45)
Durvalumab Childhood Malignant Neoplasm	AstraZeneca	P1/2	CC (45)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Childhood Malignant Neoplasm	AstraZeneca	P1/2	CC (45)
Clofarabine Childhood Malignant Neoplasm	Malika Kapadia	P1	CC (44)
Anti-Egfr Antibody-Drug Conjugate Mrg003 Childhood Malignant Neoplasm	Sun Yat-sen University	P1	CC (43)
b7h3-il7ra car-t cells Childhood Malignant Neoplasm	Chulalongkorn University	P1	CC (43)
Cba-1205 Childhood Malignant Neoplasm	Chiome Bioscience Inc.	P1	CC (41)
Uproleselan Childhood Malignant Neoplasm	Malika Kapadia	P1	CC (41)